Wire · regulatory
The TEMPO program and the future of digital mental health regulation in the US
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
The FDA's TEMPO pilot program introduces a new regulatory pathway for digital mental health devices that allows commercialization under a Quality Management System without immediate premarket authorization, targeting innovative AI-enabled mental health technologies. This regulatory sandbox aims to offer real-world data to shape evolving FDA oversight, especially for generative AI devices that currently face high barriers to traditional clearance.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You can now access a middle ground path to market in US digital mental health that cuts the long wait for FDA clearance. This opens a window to commercialise AI mental health tools under quality rules without full premarket approval yet.
◆ Coverage
1 source · 3 Nov 2026
◆ Related on Wire
◆ Topics